A double-blind, multicentric, multinational randomised study to assess the effects of one year administration of 2 g per day of strontium ranelate versus marketed bisphosphonates in women with postmenopausal osteoporosis on bone microarchitecture as measured by high-resolution peripheral-quantitative computed tomography (p-QCT)

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN82719233

Enrollment

Registered

2006-03-31

Start date

2005-10-31

Completion date

Unknown

Last updated

2018-05-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Post-menopausal osteoporosis Musculoskeletal Diseases Post-menopausal osteoporosis

Interventions

Strontium ranelate (S12911) versus marketed bisphosphonates.

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: 1. Women of at least 50 years old 2. Postmenopausal for at least five years 3. Osteoporosis

Exclusion criteria

Exclusion criteria: 1. Body mass index (BMI) 30 kg/m^2 2. Skeletal disease 3. Severe malabsorption 4. Significant and evolutive hyperthyroidism

Design outcomes

Primary

Measure	Time frame
Assessment of trabecular bone volume to tissue volume	—

Secondary

Measure	Time frame
Assessment of bone density, bone structure and bone markers	—

Countries

Australia, France, Germany, Switzerland

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Mar 31, 2026